Morning Pointe Senior Living announces Fred Hutagaol has been selected as the recipient of the Morning Pointe Scholars Endowment scholarship at Southern Adventist University. “The Morning ... more ...

Projects include creative uses of gene editing retinal degenerations, imaging technology for nerve damage, engineered immune ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Pivotal data for the fianlimab-libtayo combination in first line metastatic melanoma are also ... positive data from the Phase 3 QUASAR study in retinal vein occlusion, where EYLEA HD demonstrated ...

Traditionally, the standard treatment for resectable invasive melanoma has been surgical excision, often followed by adjuvant systemic therapy in cases of metastatic disease ... photoreceptors also ...

1 All 5 are approved for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion ... as prevent skeletal-related events associated with bone ...

PNDs are much less common than direct, metastatic, and treatment related complications ... PND can manifest as visual failure through a variety of mechanisms. Retinal photoreceptors, rods, cones, and ...

In patients with ERBB2-positive metastatic breast cancer (ERBB2+ MBC) and brain metastasis, more than half of deaths were due to central nervous system (CNS)–related causes; however, patients ...